ERBB2 and breast carcinoma: First, in the overall analysis evaluating the association of pCR outcome with HER2+ and HER2− breast cancer patients submitted to TA chemotherapy, the regression test indicated funnel plot asymmetry (p=0.03) but not the rank correlation test (p=0.34).